华海药业(600521) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached ¥2,498,671,124.15, representing a year-on-year increase of 21.36%[4] - Net profit attributable to shareholders was ¥270,842,789.22, reflecting a significant growth of 56.62% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥315,424,401.91, an increase of 67.29% year-on-year[4] - Basic and diluted earnings per share were both ¥0.19, up by 58.33% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 2,498,671,124.15, a 21.3% increase from RMB 2,058,913,113.43 in Q1 2023[16] - Net profit for Q1 2024 was RMB 273,944,434.55, representing a 62.7% increase compared to RMB 168,505,392.26 in Q1 2023[17] - The company reported a total profit of RMB 371,845,376.74 for Q1 2024, compared to RMB 240,883,645.68 in Q1 2023, marking a 54.4% increase[17] - The total comprehensive income for Q1 2024 was CNY 262,178,448.31, compared to CNY 148,538,126.97 in Q1 2023[25] Cash Flow - The net cash flow from operating activities was ¥853,246,043.03, showing a remarkable increase of 128.18% compared to the previous year[4] - Cash flow from operating activities generated RMB 853,246,043.03, significantly higher than RMB 373,933,429.54 in Q1 2023[19] - The net cash flow from investing activities was -471,690,659.45 RMB, a decrease from -521,104,230.29 RMB year-over-year[20] - The company reported a net cash flow from financing activities of 1,093,031,459.41 RMB, significantly higher than 548,627,492.74 RMB in the same quarter last year[20] - The net increase in cash and cash equivalents for the quarter was 1,485,562,536.52 RMB, compared to 367,599,362.76 RMB in the previous year[20] - The company's cash inflow from financing activities totaled 1,838,330,000.00 RMB, compared to 1,440,000,000.00 RMB in the previous year[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥20,089,317,179.86, an increase of 8.01% from the end of the previous year[4] - The company's total assets amounted to ¥20,089,317,179.86, compared to ¥18,599,969,612.84 at the end of 2023, reflecting a growth of approximately 8.0%[15] - Total current assets reached ¥8,901,797,081.57, up from ¥7,621,698,796.25, indicating an increase of about 16.8%[13] - The total liabilities increased to ¥11,599,242,747.86 from ¥10,348,854,672.57, which is an increase of approximately 12.1%[15] - The total liabilities increased to 8,776,729,779.72 RMB from 7,713,638,601.41 RMB year-over-year[22] - The company's equity attributable to shareholders rose to ¥8,319,436,460.31 from ¥8,076,851,901.19, showing an increase of about 3.0%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 72,310, with the top ten shareholders holding significant stakes[8] - The company has not reported any new strategies or significant changes in shareholder structure during the reporting period[12] Expenses - Total operating costs increased to RMB 2,099,036,620.37, up 17.1% from RMB 1,791,603,923.39 in the same period last year[16] - Research and development expenses for Q1 2024 were RMB 213,856,487.20, slightly up from RMB 202,193,404.97 in Q1 2023[16] - Sales expenses increased to RMB 490,541,619.20, a rise of 42.4% from RMB 344,775,680.27 in the previous year[16] - The company reported a financial expense of CNY 20,187,931.25 in Q1 2024, significantly reduced from CNY 68,797,147.86 in Q1 2023[24] Inventory and Investments - The company reported a total inventory of ¥3,236,962,151.59, down from ¥3,432,132,350.93, indicating a decrease of approximately 5.7%[13] - The company's inventory decreased to 2,330,768,586.18 RMB from 2,477,827,713.94 RMB year-over-year[21] - Long-term equity investments slightly decreased to ¥410,319,572.86 from ¥417,871,184.53, reflecting a decline of about 1.3%[14] - Long-term equity investments increased to 6,737,584,700.08 RMB from 6,586,268,218.76 RMB year-over-year[21] Market and Strategy - The sales team restructuring and market expansion efforts have led to improved market penetration and customer retention, contributing to revenue growth[7] - There were no new products or technologies announced in the current quarter[12]